预约演示
更新于：2025-11-13
Bevantolol Hydrochloride
盐酸贝凡洛尔
更新于：2025-11-13
概要
基本信息
药物类型 小分子化药 |
别名 (±)-bevantolol、1-((2-(3,4-dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol、1-(3,4-dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol + [17] |
作用方式 拮抗剂、阻滞剂、抑制剂 |
作用机制 ADRA1拮抗剂(肾上腺素能受体α-1家族拮抗剂)、Cav2.2阻滞剂(N-型电压门控性钙通道α-1B亚基阻滞剂)、VMAT2抑制剂(突触囊泡单胺转运体抑制剂) |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1995-03-31), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C20H28ClNO4 |
InChIKeyFJTKCFSPYUMXJB-UHFFFAOYSA-N |
CAS号42864-78-8 |
关联
2
项与 盐酸贝凡洛尔 相关的临床试验NCT05475483
Phase IIb, Randomized, Double-blind, Placebo-controlled Study in Parallel Groups Assessing the Efficacy and Safety of Two Doses of SOM3355 in Patients Suffering From Huntington's Disease With Choreic Movements
NCT03575676
Phase IIa, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of SOM3355 in Huntington's Disease (HD) Patients With Chorea Movements.
100 项与 盐酸贝凡洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸贝凡洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸贝凡洛尔 相关的专利（医药）
登录后查看更多信息
193
项与 盐酸贝凡洛尔 相关的文献（医药）2025-05-01MICROCHEMICAL JOURNAL
Quinine and vancomycin bilayer modified chiral stationary phase for enantioseparation and mechanistic study
作者: Jiang, Yanyu ; Wen, Jie ; Wang, Lujun ; Ou, Jing ; Yang, Yaxin ; Zhong, Lian ; Liao, Meifang
The achievement of universal and efficient enantioseparation by chiral stationary phase (CSP) has been considered as challenging research.In this work, a bilayer-modified chiral stationary phase (named Sil-QN-VAN) based on vancomycin and quinine was constructed first.The chiral recognition abilities of quinine and vancomycin were combined on a single column, achieving the synergistic effect for enantioseparationCompared with monochiral columns, the Sil-QN-VAN column exhibited excellent enantioseparation capability and could be used for separating various chiral drugs.The chiral separation mechanism was studied using mol. simulation techniques.In addition, the effects of temperature and injection volume on chromatog. separation were investigated.This work provides ideas for the development of efficient and universal chiral stationary phase materials.
2024-11-01Journal of Computational Biophysics and Chemistry
Molecular Docking, Quantum Mechanics and Molecular Dynamics Simulation of Anti-CAD Drugs Against High-Risk Xanthine Dehydrogenase Variants Associated with Oxidative Stress Pathways
作者: Sudhan, M. ; Ahmed, Shiek S. S. J. ; Emran, Talha Bin ; Attia, Sabry M. ; Ahmad, Sheikh F. ; Janakiraman, V.
Xanthine dehydrogenase (XDH) contributes significantly to generating reactive oxygen species in coronary artery disease (CAD). XDH has been proposed as a therapeutic target, but its genetic variants could affect protein structure and drug response. We aimed to assess protein structure modification occur due to genetic variants and to screen 215 CAD drugs for their utility in personalized CAD treatment against the XDH variants. A series of computational methods were implemented to identify pathogenic variants that cause XDH structure instability localized at the con served regions contributing to functional significance. Then, the XDH structures with the pathogenic variants were modeled using two different approaches to select the best models for docking with the CAD drugs. Finally, the stability of the docked complexes and their ability to transfer electrons were evaluated using molecular dynamics (MD) simulations and quantum mechanics/molecular mechanics (QM/MM) calculation. Among 751 variants examined; R149C and Q919R showed high pathogenicity, localized in conserved regions could alter protein structure and function. Further, docking of CAD drugs against XDH (native, R149C and Q919R) showed vericiguat with higher affinity, ranging from −7.95 kcal/mol to −10.41 kcal/mol, than the well-known XDH inhibitor (febuxostat, −5.73 kcal/mol to −8.35 kcal/mol). This indicates that vericiguat will be effective in CAD treatment, regardless of the XDH variants. Additionally, MD simulation and QM/MM confirmed vericiguat stability and electron transfer ability to form hydrogen bonds with the XDH protein. In conclusion, vericiguat will be beneficial for the personalized treatment of CAD by inhibiting XDH variants. Additional clinical studies are necessary to confirm our findings.
2024-08-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Structural characterization of extracellular polysaccharides from Phellinus igniarius SH-1 and their therapeutic effects on DSS induced colitis in mice
Article
作者: Lin, Yuanshan ; Liu, Huhu ; Qin, Jing ; Tian, Yun ; Zhang, Qiaoyi ; Zhao, Rou ; Huang, Ting ; Zhu, Lin
Phellinus igniarius is a valuable medicinal and edible mushroom, and its polysaccharides exhibit excellent anti-inflammatory activity. During liquid fermentation to produce P. igniarius mycelia, the fermentation liquid is often discarded, but it contains extracellular polysaccharides. To better utilize these resources, P. igniarius SH-1 was fermented in a 100 L fermenter, and PIPS-2 was isolated and purified from the fermentation broth. The structural characteristics and anti-inflammatory activity of PIPS-2 were determined. PIPS-2 had a molecular weight of 22.855 kDa and was composed of galactose and mannose in a molar ratio of 0.38:0.62. Structural analysis revealed that the main chain of PIPS-2 involved →2)-α-D-Manp-(1 → 3)-β-D-Galf-(1→, and the side chains involved α-D-Manp-(1 → 6)-α-D-Manp-(1→, α-D-Manp-(1 → 3)-α-D-Manp-(1→, and α-D-Manp-(1. PIPS-2 alleviated the symptoms of dextran sodium sulfate (DSS)-induced colitis in mice, improved the imbalance of inflammatory factors and antioxidant enzymes, and increased short-chain fatty acid contents. Combining the intestinal flora and metabolite results, PIPS-2 was found to regulate the abundance of Firmicutes, Lachnospiraceae_NK4A136_group, Proteobacteria, Bacteroides, and many serum metabolites including hexadecenal, copalic acid, 8-hydroxyeicosatetraenoic acid, artepillin C, and uric acid, thereby ameliorating metabolite related disorders in mice with colitis. In summary, PIPS-2 may improve colitis in mice by regulating the gut microbiota and metabolites.
100 项与 盐酸贝凡洛尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 中国 | 2002-12-11 | |
| 高血压 | 日本 | 1995-03-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 亨廷顿舞蹈病 | 临床2期 | 西班牙 | 2018-08-08 | |
| 迟发性运动障碍 | 临床2期 | 西班牙 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 139 | Placebo capsules (Placebo) | 製鹽觸鹽鏇鬱構繭觸蓋(壓醖衊遞網鏇遞築窪夢) = 鹽繭顧願觸築艱糧醖鹽 廠遞顧膚衊顧積鏇壓範 (鹹鹽鹹遞簾鬱選醖衊網, 壓膚蓋鏇鏇糧醖艱夢觸 ~ 積範夢蓋艱築簾築夢衊) 更多 | - | 2025-08-28 | ||
(SOM3355 400 mg/Day) | 製鹽觸鹽鏇鬱構繭觸蓋(壓醖衊遞網鏇遞築窪夢) = 夢選鹹襯窪餘鹽淵襯願 廠遞顧膚衊顧積鏇壓範 (鹹鹽鹹遞簾鬱選醖衊網, 膚醖繭膚蓋製網選鬱鏇 ~ 衊壓鏇襯壓鹽夢憲範構) 更多 | ||||||
临床2期 | 32 | 願獵蓋範淵積淵齋鏇夢(觸鏇鹹鏇醖鬱製獵獵繭) = The most frequent adverse events during SOM3355 administration were mild to moderate 鹹膚壓積餘選膚窪餘範 (壓遞齋淵顧製艱膚築艱 ) | - | 2022-12-09 | |||
临床2期 | 32 | 鏇餘鹹構淵襯窪鹽淵範(願醖遞淵範觸觸淵齋醖) = 鬱範鬱簾齋膚簾衊構衊 壓蓋餘壓廠製壓鏇鏇廠 (網膚範鹹製淵網憲網鬱 ) | 积极 | 2021-10-04 | |||
Placebo | - |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用